TB-500 Fragment (17-23)

TB-500 Fragment (17-23) Tissue Regeneration Analysis

TB-500 Fragment (17-23) belongs to the category of cutting-edge cyto-protective and regenerative molecules. Research indicates profound applications across tendon, muscular, and skeletal recovery pathways.

Molecular Specification

Parameter	Value
Formula	C38H68N10O14
Molecular Mass	889.0 g/mol
Standard Purity	>98.0%
Physical State	White crystalline solid

Figure 1: TB-500 Fragment (17-23) Cellular Binding Model

Regenerative Pathway

The systematic repair protocol engaged by the peptide compound:

1. An isolated, 7-amino-acid active sequence of the full length Thymosin Beta-4.
2. It specifically retains the actin-binding domains of the parent compound.
3. Possesses a much smaller molecular weight allowing for superior tissue penetration.
4. Binds rapidly to G-actin, increasing localized cellular mobility.
5. Initiates focal-adhesion kinase breakdown for improved cell migration.

Figure 2: Rate of Tissue Regrowth over Baseline

Primary Research Vectors

• Study 1: Offers an extreme concentration of the core actin-regulating mechanism.
• Study 2: Primarily researched for acute wound healing and skin elasticity.
• Study 3: Displays a potentially faster absorption curve than the 43-amino acid parent.

The Active Core of Thymosin Beta-4

TB-500 Fragment 17-23 (also designated TB4-Frag or Ac-SDKP extended sequence) represents the minimal actin-binding domain of the full 43-amino acid Thymosin Beta-4 protein. This 7-amino acid fragment (molecular weight 889 Da) retains the critical LKKTET sequence responsible for G-actin interaction and the wound-healing properties of the parent molecule. The significantly smaller size offers potential advantages in tissue penetration, blood-brain barrier crossing, and manufacturing cost compared to the full-length peptide.

1. The fragment binds the hydrophobic cleft of G-actin at the barbed end, identical to full-length TB-500, preventing spontaneous polymerization.
2. Despite its truncated size, Fragment 17-23 maintains cell migration-promoting activity at comparable molar concentrations to the full protein.
3. The reduced molecular weight (889 Da vs 4,963 Da) allows faster tissue diffusion and potentially improved bioavailability.
4. In scratch-wound assays, Fragment 17-23 produces keratinocyte migration rates within 85–90% of full-length TB-500.
5. The fragment may access intracellular targets more readily due to its smaller hydrodynamic radius, enhancing direct actin modulation.

Research Comparison & Applications

• vs. Full-Length TB-500: The fragment lacks the N-terminal Ac-SDKP domain responsible for anti-fibrotic effects. Researchers targeting fibrosis specifically may prefer full-length TB-500.
• Wound Models: Fragment 17-23 demonstrates comparable wound closure rates to TB-500 in superficial wound models but may show reduced efficacy in deep tissue injuries requiring anti-inflammatory components.
• Cost Efficiency: Solid-phase synthesis of a 7-mer peptide is substantially less expensive than a 43-mer, making Fragment 17-23 an economical option for large-scale research.
• Combination Protocols: Often combined with BPC-157 in tissue repair research, where BPC-157 provides the VEGF/angiogenic component and the fragment provides the actin-remodeling component.
• Storage: The fragment is lyophilized and reconstituted identically to full TB-500. Store at −20°C lyophilized; 2–8°C reconstituted, use within 21 days.